Editorial: Health-Related Complications of Acromegaly.
作者信息
Bolanowski Marek, Boguszewski Cesar L, Colao Annamaria, Jawiarczyk-Przybyłowska Aleksandra
机构信息
Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wrocław, Poland.
Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Paraná, Curitiba, Brazil.
出版信息
Front Endocrinol (Lausanne). 2020 Jul 29;11:496. doi: 10.3389/fendo.2020.00496. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Health-Related Complications of Acromegaly.社论：肢端肥大症的健康相关并发症
Front Endocrinol (Lausanne). 2020 Jul 29;11:496. doi: 10.3389/fendo.2020.00496. eCollection 2020.
2
A consensus on the diagnosis and treatment of acromegaly complications.关于肢端肥大症并发症的诊断和治疗的共识。
Pituitary. 2013 Sep;16(3):294-302. doi: 10.1007/s11102-012-0420-x.
3
Systemic complications of acromegaly: epidemiology, pathogenesis, and management.肢端肥大症的全身并发症：流行病学、发病机制及管理
Endocr Rev. 2004 Feb;25(1):102-52. doi: 10.1210/er.2002-0022.
4
Relationship between symptoms of acromegely and its complications, principally cardiovascular in 86 patients.86例肢端肥大症患者的症状与其并发症（主要是心血管并发症）之间的关系。
Acta Univ Carol Med (Praha). 1970;16(5):553-69.
5
The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.长期生长激素和胰岛素样生长因子-1 暴露对肢端肥大症治疗患者心血管、脑血管和代谢合并症发展的影响。
Clin Endocrinol (Oxf). 2011 Aug;75(2):220-5. doi: 10.1111/j.1365-2265.2011.04019.x.
6
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.肢端肥大症的全身并发症及当前治疗现状的影响：最新进展。
Endocr Rev. 2019 Feb 1;40(1):268-332. doi: 10.1210/er.2018-00115.
7
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的肝外表现和并发症。
Future Med Chem. 2019 Aug;11(16):2171-2192. doi: 10.4155/fmc-2019-0003.
8
Secondary oxalosis of bone in chronic renal failure. A histopathological study of three cases.慢性肾衰竭时骨的继发性草酸沉积症。三例组织病理学研究。
J Bone Joint Surg Am. 1974 Mar;56(2):387-95.
9
Rheumatologic and skeletal changes in acromegaly.肢端肥大症的风湿性和骨骼改变。
Endocrinol Metab Clin North Am. 1992 Sep;21(3):615-31.
10
Chronic kidney disease and its complications.慢性肾脏病及其并发症。
Prim Care. 2008 Jun;35(2):329-44, vii. doi: 10.1016/j.pop.2008.01.008.
引用本文的文献
1
Myokines in Acromegaly: An Altered Irisin Profile.肢端肥大症中的肌肉因子：鸢尾素谱的改变。
Front Endocrinol (Lausanne). 2021 Nov 2;12:728734. doi: 10.3389/fendo.2021.728734. eCollection 2021.
本文引用的文献
1
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.肢端肥大症合并症的诊断与治疗共识：更新版。
J Clin Endocrinol Metab. 2020 Apr 1;105(4). doi: 10.1210/clinem/dgz096.
2
Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study.肢端肥大症患者的非侵入性 DXA 骨结构评估：一项横断面研究。
Eur J Endocrinol. 2019 Mar 1;180(3):201-211. doi: 10.1530/EJE-18-0881.
3
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.肢端肥大症继发糖尿病：病理生理学、临床特征及治疗效果
Front Endocrinol (Lausanne). 2018 Jul 6;9:358. doi: 10.3389/fendo.2018.00358. eCollection 2018.
4
Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis.肢端肥大症患者的死亡率在过去十年中有所下降：系统评价和荟萃分析。
Eur J Endocrinol. 2018 Jul;179(1):59-71. doi: 10.1530/EJE-18-0255. Epub 2018 May 15.
5
Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature.肢端肥大症患者的癌症发病率：一项队列研究和文献荟萃分析。
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2182-2188. doi: 10.1210/jc.2017-02457.
6
Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy.肢端肥大症患者的冠状动脉微血管功能障碍可能与 IGF-1 有关，并且可以通过治疗得到恢复。
Atherosclerosis. 2018 Feb;269:100-105. doi: 10.1016/j.atherosclerosis.2017.12.019. Epub 2017 Dec 24.
7
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.帕西瑞肽长效释放制剂治疗肢端肥大症的安全性和耐受性——来自肢端肥大症开放标签、多中心、用于治疗有接受药物治疗需求患者的安全性监测项目（ACCESS）研究的结果
Endocrine. 2017 Jan;55(1):247-255. doi: 10.1007/s12020-016-1182-4. Epub 2016 Nov 28.
8
The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes.墨西哥肢端肥大症登记处：诊断时的临床和生化特征及治疗结果
J Clin Endocrinol Metab. 2016 Nov;101(11):3997-4004. doi: 10.1210/jc.2016-1937. Epub 2016 Jul 18.
9
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.肢端肥大症诊断与管理中的挑战：关注合并症
Pituitary. 2016 Aug;19(4):448-57. doi: 10.1007/s11102-016-0725-2.
10
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.培高利特对比奥曲肽或兰瑞肽治疗未能充分控制的肢端肥大症患者（PAOLA）：一项随机、3 期试验。
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.
Zotero 插件